FDA Brief

Warning letters Food

FDA warning letter to

Calroy Health Sciences, LLC

LowIssued Nov 14, 2022Posted Nov 17, 2022Center for Food Safety and Applied Nutrition (CFSAN)

FDA told Calroy Health Sciences that website claims make its Arterosil supplement an unapproved drug for treating disease.

What happened

FDA reviewed www.arterosil.com in October 2022 and found the company takes orders there for Arterosil. FDA said website claims about plaque, diabetes, stroke, hypertension, and neuropathy show Arterosil is intended to cure, mitigate, treat, or prevent disease. FDA calls it a "new drug" (not generally recognized as safe and effective for those uses and not FDA-approved) and says it is misbranded because it lacks adequate directions for use.

What FDA found

  1. FDA treats Arterosil as a drug because website claims say it can treat or prevent diseases such as heart disease, diabetes, stroke, hypertension, and neuropathy.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]
  2. Arterosil is not generally recognized as safe and effective for those claimed disease uses, so FDA classifies it as a new drug.

    section 201(p) of the Act [21 U.S.C. 321(p)]
  3. The company offered Arterosil for interstate commerce for drug uses without the required FDA approval.

    sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]
  4. Arterosil lacks adequate directions for use because its claimed diseases cannot be safely self-diagnosed or self-treated without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]
  5. The company introduced or delivered a misbranded drug into interstate commerce.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks Calroy to notify it in writing within 15 working days of the steps taken to address the violations, including how it will prevent recurrence and related documents. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • dietary supplement brands that make disease claims
  • marketing and compliance teams for supplement websites
  • online sellers of supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk